
  
    
      
        Introduction_NNP
        Smallpox_NNP ,_, while_IN not_RB found_VBD in_IN the_DT world_NN 's_POS population_NN at_IN
        present_JJ ,_, remains_VBZ a_DT potential_JJ health_NN hazard_NN especially_RB due_JJ
        to_TO the_DT possibility_NN of_IN its_PRP$ use_NN as_IN a_DT bioweapon_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN
        ._. There_EX is_VBZ currently_RB no_DT accepted_VBN treatment_NN for_IN smallpox_NN ,_,
        although_IN a_DT number_NN of_IN agents_NNS have_VBP been_VBN evaluated_VBN [_NN 6_CD ]_NN ._.
        Therefore_RB ,_, new_JJ therapeutic_JJ or_CC virucidal_NN agents_NNS could_MD have_VB
        great_JJ utility_NN in_IN slowing_VBG both_DT the_DT progression_NN and_CC spread_NN of_IN
        the_DT disease_NN in_IN an_DT epidemic_NN situation_NN ._. In_IN the_DT present_JJ study_NN ,_,
        we_PRP have_VBP investigated_VBN the_DT potential_NN of_IN porphyrins_NNS (_( Por_NNP )_) and_CC
        phthalocyanines_NNS (_( Pc_NNP )_) to_TO prevent_VB infection_NN by_IN vaccinia_NN virus_NN
        in_IN cell_NN culture_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Porphyrins_NNP and_CC phthalocyanines_NNS
          Porphyrins_NNP were_VBD obtained_VBN from_IN Midcentury_NNP Chemicals_NNPS
          (_( Chicago_NNP ,_, Illinois_NNP )_) or_CC Frontier_NNP Scientific_NNP (_( Logan_NNP ,_, Utah_NNP )_)
          and_CC used_VBN as_IN received_VBN ._. Porphyrin_NNP designations_NNS are_VBP as_IN
          follows_VBZ :_: PP_NNP ,_, protoporphyrin_NN IX_CD ;_: HP_NNP ,_, hematoporphyrin_NN IX_CD ;_:
          TPP_NNP ,_, 
          meso_NN -_: tetraphenylporphine_NN ;_: TNapPS_NNP ,_,
          sulfonated_JJ 5_CD ,_, 10_CD ,_, 15_CD ,_, 20_CD -_: tetra-naphthalen-_JJ 1_CD -_: yl-porphyrin_JJ ;_:
          TAnthPS_NNP ,_, sulfonated_JJ
          5_CD ,_, 10_CD ,_, 15_CD ,_, 20_CD -_: tetra-anthracen-_JJ 9_CD -_: yl-porphyrin_JJ ._. Other_JJ
          porphyrins_NNS are_VBP tetraphenylporphyrin_NN derivatives_NNS ,_, e_SYM ._. g_SYM ._. ,_,
          TPP_NNP 2_CD F_NN is_VBZ tetraphenylporphyrin_NN with_IN a_DT fluoro_NN group_NN at_IN the_DT
          2_CD -_: position_NN on_IN each_DT phenyl_NN ring_NN ._. An_DT "_'' S_NNP "_'' at_IN the_DT end_NN of_IN the_DT
          name_NN indicates_VBZ that_IN the_DT parent_NN porphyrin_NN was_VBD sulfonated_JJ ._.
          In_IN most_JJS cases_NNS ,_, these_DT are_VBP mixtures_NNS with_IN variable_JJ numbers_NNS
          of_IN sulfonates_NNS and_CC /_NN or_CC positions_NNS of_IN the_DT sulfonates_NNS on_IN the_DT
          ring_NN ._. The_DT sulfonated_JJ copper_NN phthalocyanine_NN [_NN sold_VBN as_IN
          CuPcS_NNP (_( 3_CD ,_, 4_CD '_POS ,_, 4_CD "_'' ,_, 4_CD "_'' '_POS )_) ]_NN was_VBD purchased_VBN from_IN Aldrich_NNP ._.
        
        
          Cell_NNP lines_NNS and_CC virus_NN strains_NNS
          CV-_NNP 1_CD ,_, BSC-_NNP 40_CD and_CC TK_NNP -_: 143_CD B_NNP cells_NNS were_VBD maintained_VBN in_IN
          Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN (_( DMEM_NNP )_) supplemented_JJ
          with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) and_CC incubated_JJ at_IN 37_CD °_NN C_NNP ,_,
          5_CD %_NN CO_NNP 
          2_CD ._. CV-_NNP 1_CD cells_NNS were_VBD utilized_JJ for_IN virus_NN
          titer_NN determinations_NNS and_CC TK_NNP -_: 143_CD B_NNP cells_NNS were_VBD used_VBN in_IN
          virus_NN stock_NN preparations_NNS ._. HeLa_NNP S_NNP 3_CD cells_NNS were_VBD grown_VBN at_IN
          37_CD °_NN C_NNP in_IN RPMI_NNP 1640_CD culture_NN medium_NN supplemented_JJ with_IN 10_CD %_NN
          FBS_NNP and_CC the_DT antibiotics_NNS penicillin_NN and_CC streptomycin_NN ._.
        
        
          Growth_NN of_IN vaccinia_NN virus_NN (_( VV_NNP )_)
          Two_CD strains_NNS of_IN vaccinia_NN virus_NN (_( VV_NNP )_) were_VBD used_VBN in_IN this_DT
          study_NN :_: the_DT Western_NNP Reserve_NNP (_( WR_NNP )_) and_CC International_NNP Health_NNP
          Department-_NNP J_NNP (_( IHD-J_NNP )_) strains_NNS ._. The_DT WR_NNP strain_NN ,_, produced_VBN by_IN
          Virotech_NNP International_NNP (_( Rockville_NNP ,_, MD_NNP )_) ,_, was_VBD a_DT gift_NN from_IN
          Dr_NNP ._. Mark_NNP Feinberg_NNP (_( Emory_NNP University_NNP )_) ._. The_DT IHD-J_NNP strain_NN
          was_VBD grown_VBN as_IN described_VBN previously_RB [_NN 7_CD ]_NN ._. TK_NNP -_: 143_CD B_NNP cells_NNS ,_,
          grown_VBN in_IN roller_NN bottles_NNS ,_, were_VBD infected_VBN with_IN the_DT WR_NNP strain_NN
          of_IN the_DT virus_NN and_CC incubated_JJ for_IN 2_CD days_NNS at_IN 37_CD °_NN C_NNP ._. The_DT cells_NNS
          were_VBD collected_VBN ,_, resuspended_JJ in_IN a_DT buffered_JJ solution_NN of_IN 10_CD
          mM_NN Tris-_NNP HCl_NNP (_( pH_NN 9_CD )_) and_CC homogenized_JJ with_IN 20_CD strokes_NNS in_IN a_DT
          Dounce_NNP homogenizer_NN ._. Large_JJ debris_NN and_CC nuclei_NN were_VBD
          sedimented_JJ by_IN centrifugation_NN at_IN 1_CD ,_, 400_CD rpm_NN for_IN 5_CD min_NN ._. The_DT
          supernatant_NN was_VBD collected_VBN and_CC trypsin_NN (_( 250_CD μg_NN /_NN mL_NN )_) added_VBD ._.
          This_DT was_VBD then_RB loaded_VBN on_IN a_DT 36_CD %_NN sucrose_NN cushion_NN and_CC the_DT
          virus_NN pelleted_JJ by_IN centrifugation_NN at_IN 13_CD ,_, 500_CD rpm_NN for_IN 80_CD min_NN
          using_VBG a_DT Beckman_NNP SW_NNP 28_CD rotor_NN ._. Extracellular_NNP particles_NNS of_IN
          IHD-J_NNP were_VBD obtained_VBN by_IN infecting_VBG TK_NNP -_: 143_CD B_NNP cells_NNS ._. After_IN 24_CD
          h_NN incubation_NN at_IN 37_CD °_NN C_NNP ,_, the_DT culture_NN medium_NN was_VBD pre-cleared_JJ
          and_CC the_DT virus_NN was_VBD concentrated_VBN by_IN centrifugation_NN at_IN
          13_CD ,_, 500_CD rpm_NN for_IN 80_CD min_NN in_IN a_DT SW_NNP 28_CD rotor_NN and_CC resuspended_JJ in_IN
          1_CD mM_NN Tris-_NNP HCl_NNP (_( pH_NN 9_CD )_) ._.
        
        
          Prevention_NNP of_IN virus_NN infection_NN
          A_DT plaque_NN assay_NN was_VBD used_VBN to_TO determine_VB the_DT ability_NN of_IN
          test_NN compounds_NNS to_TO prevent_VB infection_NN ._. Compound_NN stock_NN
          solutions_NNS ,_, 5_CD mg_NN /_NN mL_NN ,_, were_VBD diluted_VBN 10_CD -_: fold_VB in_IN DMEM_NNP without_IN
          FBS_NNP and_CC mixed_VBN with_IN virus_NN particles_NNS to_TO five_CD final_JJ
          concentrations_NNS :_: 50_CD ,_, 10_CD ,_, 2_CD ,_, 0_CD ._. 4_CD and_CC 0_CD ._. 08_CD μg_NN /_NN mL_NN ._. After_IN 1_CD h_NN
          incubation_NN (_( in_IN the_DT dark_JJ )_) the_DT virus-drug_JJ mixture_NN was_VBD
          diluted_VBN 10_CD -_: fold_VB in_IN DMEM_NNP (_( without_IN FBS_NNP )_) to_TO 500_CD μL_NN and_CC 100_CD
          μL_NN added_VBD to_TO each_DT well_RB of_IN confluent_NN CV-_NNP 1_CD or_CC BSC-_NNP 40_CD cells_NNS
          grown_VBN in_IN 24_CD -_: well_RB plates_NNS ._. This_DT afforded_VBN 200_CD pfu_NN /_NN well_RB (_( 1_CD ×_NN
          10_CD -_: 3_CD pfu_NN /_NN cell_NN )_) ._. Following_VBG virus-drug_JJ adsorption_NN onto_IN the_DT
          monolayer_NN ,_, 1_CD h_NN at_IN 37_CD °_NN C_NNP ,_, cell_NN monolayers_NNS were_VBD washed_VBN twice_RB
          PBS_NNP to_TO remove_VB residual_JJ virus-drug_JJ mixture_NN ._. New_JJ growth_NN
          medium_NN supplemented_JJ with_IN 2_CD ._. 5_CD %_NN FBS_NNP was_VBD then_RB added_VBN to_TO each_DT
          well_RB ._.
          A_DT plaque_NN assay_NN was_VBD used_VBN to_TO determine_VB the_DT quantity_NN of_IN
          infectious_JJ particles_NNS remaining_VBG after_IN drug_NN treatment_NN ._. Two_CD
          days_NNS after_IN infection_NN ,_, the_DT growth_NN medium_NN was_VBD removed_VBN and_CC
          the_DT cells_NNS washed_VBN twice_RB with_IN PBS_NNP ._. A_DT solution_NN of_IN 0_CD ._. 1_CD %_NN
          crystal_NN violet_NN ,_, 10_CD %_NN formaldehyde_NN in_IN phosphate_NN buffered_JJ
          saline_NN (_( PBS_NNP )_) was_VBD then_RB added_VBN to_TO the_DT wells_NNS ._. After_IN 30_CD min_NN
          incubation_NN ,_, the_DT stain_VB was_VBD removed_VBN and_CC the_DT wells_NNS washed_VBN
          with_IN PBS_NNP and_CC allowed_VBN to_TO dry_VB ._. The_DT number_NN of_IN plaques_NNS was_VBD
          then_RB determined_VBN and_CC activity_NN calculated_VBN based_VBN on_IN the_DT
          reduction_NN in_IN average_JJ number_NN of_IN plaques_NNS ,_, in_IN wells_NNS where_WRB
          the_DT compound_NN was_VBD pre-incubated_JJ with_IN the_DT virus_NN ,_, compared_VBN
          to_TO the_DT control_NN wells_NNS inoculated_JJ with_IN untreated_JJ virus_NN ._. As_IN
          an_DT alternative_NN to_TO the_DT liquid_JJ overlay_NN ,_, agar_NN overlays_VBZ were_VBD
          also_RB investigated_VBN ._. Similar_JJ results_NNS were_VBD obtained_VBN with_IN
          both_DT assays_NNS ._. Hence_RB ,_, further_JJ plaque_NN assays_NNS were_VBD done_VBN using_VBG
          liquid_JJ overlays_VBZ ._.
          EC_NNP 
          50_CD values_NNS were_VBD calculated_VBN as_IN response_NN
          =_SYM min_NN +_NN (_( max-min_JJ )_) /_NN (_( 1_CD +_NN 10_CD [_NN exp_NN (_( log_VB [_NN drug_NN ]_NN -_: logEC_NN 
          50_CD )_) ]_NN using_VBG Kaleidagraph_NNP (_( Synergy_NNP
          Software_NNP ,_, Reading_VBG ,_, Pennsylvania_NNP )_) ._. Reported_NNP EC_NNP 
          50_CD values_NNS are_VBP the_DT average_JJ and_CC standard_JJ
          deviation_NN of_IN three_CD separate_JJ determinations_NNS ,_, each_DT
          replicated_VBN three_CD times_NNS ._.
        
        
          Inhibition_NNP of_IN virus_NN yield_NN
          Confluent_NNP monolayers_NNS of_IN CV-_NNP 1_CD cells_NNS were_VBD infected_VBN with_IN
          5_CD ×_NN 10_CD 5_CD pfu_NN /_NN well_RB (_( 2_CD ._. 5_LS pfu_NN /_NN cell_NN )_) of_IN WR_NNP for_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP ._.
          The_DT cells_NNS were_VBD then_RB washed_VBN twice_RB with_IN PBS_NNP to_TO remove_VB any_DT
          residual_JJ virus_NN ._. Compound_NN stock_NN solutions_NNS ,_, 5_CD mg_NN /_NN mL_NN ,_, were_VBD
          diluted_VBN in_IN DMEM_NNP with_IN 2_CD ._. 5_CD %_NN FBS_NNP to_TO final_JJ concentrations_NNS of_IN
          50_CD or_CC 25_CD μg_NN /_NN mL_NN ._. This_DT media_NNS containing_VBG compounds_NNS (_( 500_CD μL_NN )_)
          was_VBD then_RB added_VBN to_TO the_DT cells_NNS ._. At_IN 16_CD h_NN post-infection_JJ ,_, cell_NN
          monolayers_NNS and_CC culture_NN medium_NN were_VBD harvested_VBN and_CC
          subjected_VBN to_TO several_JJ cycles_NNS of_IN freeze_NN /_NN thawing_VBG to_TO release_VB
          intracellular_NN and_CC extracellular_NN virus_NN particles_NNS ._. A_DT plaque_NN
          assay_NN on_IN CV-_NNP 1_CD cells_NNS was_VBD used_VBN to_TO determine_VB the_DT virus_NN
          titer_NN ._. CV-_NNP 1_CD cells_NNS were_VBD infected_VBN with_IN the_DT virus_NN inoculum_NN
          for_IN 1_CD h_NN ;_: the_DT growth_NN medium_NN was_VBD removed_VBN and_CC 2_CD ._. 5_CD %_NN FBS_NNP in_IN
          DMEM_NNP added_VBD to_TO the_DT cells_NNS ._. After_IN 2_CD days_NNS ,_, the_DT cells_NNS were_VBD
          washed_VBN with_IN PBS_NNP and_CC later_RB stained_JJ with_IN a_DT solution_NN of_IN 0_CD ._. 1_CD %_NN
          crystal_NN violet_NN ,_, 10_CD %_NN formaldehyde_NN in_IN PBS_NNP ,_, and_CC the_DT viral_JJ
          plaque_NN number_NN was_VBD counted_VBN ._. To_TO determine_VB if_IN viral_JJ
          inactivation_NN occurs_VBZ after_IN cell_NN lysis_NNS ,_, the_DT cell_NN monolayers_NNS
          were_VBD washed_VBN three_CD times_NNS with_IN DMEM_NNP to_TO remove_VB the_DT compounds_NNS
          then_RB harvested_VBN and_CC subjected_VBN to_TO several_JJ cycles_NNS of_IN
          freeze_NN /_NN thawing_VBG to_TO release_VB intracellular_NN virus_NN
          particles_NNS ._.
        
        
          Cell_NNP proliferation_NN assay_NN
          Cell_NNP proliferation_NN was_VBD measured_VBN by_IN [_NN 3_CD H_NNP ]_NN -_: thymidine_NN
          uptake_NN [_NN 8_CD ]_NN ._. HeLa_NNP S_NNP 3_CD cells_NNS (_( 3_CD ×_NN 10_CD 4_CD cells_NNS /_NN well_RB )_) were_VBD
          incubated_JJ in_IN 96_CD -_: well_RB plates_NNS in_IN the_DT presence_NN of_IN varying_VBG
          concentrations_NNS of_IN the_DT tetrapyrroles_NNS for_IN 2_CD days_NNS at_IN 37_CD °_NN C_NNP ,_,
          after_IN which_WDT 3_CD H-T_NNP dR_NN (_( 1_CD μCi_NN /_NN well_RB )_) was_VBD added_VBN ._. The_DT cells_NNS were_VBD
          further_JJ incubated_JJ for_IN 16_CD h_NN ,_, then_RB harvested_VBN and_CC 3_CD H-T_NNP dR_NN
          incorporation_NN monitored_VBN by_IN using_VBG a_DT liquid_JJ scintillation_NN
          counter_NN ._. Data_NNP are_VBP from_IN a_DT single_JJ experiment_NN ._.
        
        
          Cytotoxicity_NNP of_IN active_JJ tetrapyrroles_NNS
          CV-_NNP 1_CD and_CC BSC-_NNP 40_CD cells_NNS were_VBD seeded_VBN at_IN a_DT concentration_NN
          of_IN 3_CD ._. 5_CD ×_NN 10_CD 4_CD cells_NNS /_NN well_RB in_IN a_DT 96_CD -_: well_RB plate_NN and_CC allowed_VBN to_TO
          attach_VB overnight_JJ ,_, after_IN which_WDT they_PRP were_VBD ~_NN 80_CD %_NN confluent_NN ._.
          Compounds_NNP in_IN DMEM_NNP with_IN 10_CD %_NN FBS_NNP were_VBD added_VBN to_TO the_DT cells_NNS ._.
          After_IN 2_CD days_NNS ,_, a_DT trypan_NN blue_JJ viability_NN assay_NN [_NN 9_CD ]_NN was_VBD
          performed_VBN ._. The_DT 50_CD %_NN cytotoxic_JJ concentration_NN (_( CC_NNP 
          50_CD )_) is_VBZ the_DT concentration_NN required_VBN to_TO
          reduce_VB viable_JJ cell_NN numbers_NNS by_IN 50_CD %_NN relative_JJ to_TO untreated_JJ
          control_NN cell_NN numbers_NNS ._. This_DT was_VBD determined_VBN by_IN incubation_NN
          in_IN growth_NN medium_NN containing_VBG serial_NN dilutions_NNS of_IN compounds_NNS
          in_IN the_DT range_NN of_IN 50_CD -_: 2000_CD μg_NN /_NN mL_NN for_IN 2_CD days_NNS ,_, after_IN which_WDT
          the_DT viable_JJ cell_NN numbers_NNS were_VBD determined_VBN ._. To_TO determine_VB the_DT
          effect_NN of_IN the_DT compounds_NNS on_IN cell_NN proliferation_NN ,_, after_IN 24_CD h_NN
          incubation_NN ,_, the_DT cells_NNS were_VBD washed_VBN and_CC further_JJ incubated_JJ
          in_IN the_DT absence_NN of_IN the_DT compounds_NNS for_IN 1_CD day_NN ,_, and_CC then_RB a_DT
          trypan_NN blue_JJ assay_NN was_VBD done_VBN ._. Data_NNP are_VBP from_IN a_DT single_JJ
          experiment_NN ._.
        
        
          Cytostatic_NNP activity_NN
          CV-_NNP 1_CD cells_NNS were_VBD seeded_VBN at_IN 3_CD ._. 5_CD ×_NN 10_CD 3_CD cells_NNS /_NN well_RB (_( in_IN
          growth_NN medium_NN )_) in_IN a_DT 96_CD -_: well_RB plate_NN and_CC allowed_VBN to_TO attach_VB
          overnight_JJ ;_: the_DT compounds_NNS (_( in_IN growth_NN medium_NN )_) were_VBD then_RB
          added_VBN ._. Following_VBG a_DT 24_CD h_NN incubation_NN ,_, the_DT cells_NNS were_VBD
          counted_VBN ._.
        
      
      
        Results_NNS
        Initial_JJ screening_NN of_IN porphyrins_NNS and_CC phthalocyanines_NNS
        (_( Figure_NN 1_LS )_) involved_VBN more_JJR than_IN 100_CD different_JJ compounds_NNS ._.
        These_DT compounds_NNS were_VBD pre-incubated_JJ with_IN the_DT virus_NN and_CC then_RB
        the_DT mixture_NN was_VBD inoculated_JJ on_IN CV-_NNP 1_CD cells_NNS and_CC residual_JJ virus_NN
        titers_NNS were_VBD determined_VBN by_IN plaque_NN assay_NN ._. Based_VBN on_IN the_DT
        results_NNS obtained_VBN ,_, we_PRP were_VBD able_JJ to_TO determine_VB the_DT most_RBS active_JJ
        compounds_NNS ,_, that_WDT is_VBZ ,_, compounds_NNS at_IN 50_CD μg_NN /_NN mL_NN that_IN inactivated_JJ
        the_DT virus_NN completely_RB (_( no_DT plaques_NNS seen_VBN )_) (_( Figure_NN 2_LS )_) ._. These_DT
        were_VBD chosen_VBN as_IN candidates_NNS for_IN further_JJ study_NN ._.
        Approximately_RB 20_CD natural_JJ porphyrins_NNS (_( based_VBN on_IN the_DT
        protoporphyrin_NN ring_NN skeleton_NN of_IN hemin_NN )_) were_VBD evaluated_VBN ._. In_IN
        general_JJ ,_, structures_NNS with_IN the_DT hematoporphyrin_NN ring_NN (_( i_NNP ._. e_SYM ._. ,_,
        hydroxyethyl_NN groups_NNS at_IN the_DT 2_CD -_: and_CC 4_CD -_: positions_NNS ,_, see_VB CuHPIX_NNP
        in_IN Figure_NN 1_LS )_) were_VBD found_VBN to_TO be_VB more_RBR active_JJ than_IN structures_NNS
        with_IN the_DT protoporphyrin_NN (_( see_VB ZnPPIX_NNP in_IN Figure_NN 1_LS )_) ,_,
        mesoporphyrin_NN ,_, deuteroporphyrin_NN or_CC deuteroporphyrin_NN
        disulfonic_JJ acid_NN rings_NNS (_( ethyl_NN ,_, hydrogen_NN or_CC sulfonate_NN at_IN
        positions_NNS 2_CD and_CC 4_CD ,_, respectively_RB )_) ._. CuHPIX_NNP and_CC ZnPPIX_NNP were_VBD
        evaluated_VBN in_IN more_JJR detail_NN ._. CuHPIX_NNP was_VBD more_RBR active_JJ than_IN
        ZnPPIX_NNP [_NN e_SYM ._. g_SYM ._. ,_, EC_NNP 
        50_CD values_NNS of_IN 1_CD ._. 5_CD vs_NNS ._. 25_CD ._. 7_CD μg_NN /_NN mL_NN for_IN
        IHD-J_NNP (_( in_IN CV-_NNP 1_CD cells_NNS )_) ]_NN but_CC neither_DT was_VBD as_RB active_JJ as_IN the_DT
        sulfonated_JJ porphyrins_NNS (_( 
        vide_NN infra_NN )_) ._. The_DT ability_NN of_IN these_DT
        compounds_NNS to_TO prevent_VB infection_NN was_VBD also_RB compared_VBN in_IN BSC-_NNP 40_CD
        cells_NNS ._. Generally_RB ,_, the_DT EC_NNP 
        50_CD data_NNS obtained_VBN from_IN both_DT cell_NN lines_NNS
        were_VBD of_IN the_DT same_JJ order_NN of_IN magnitude_NN ;_: however_RB ,_, in_IN the_DT BSC-_NNP 40_CD
        cell_NN line_NN ,_, the_DT WR_NNP strain_NN of_IN the_DT virus_NN showed_VBD a_DT hundred-fold_JJ
        greater_JJR sensitivity_NN to_TO CuHPIX_NNP as_IN compared_VBN with_IN CV-_NNP 1_CD cells_NNS
        (_( Table_NNP 1_LS )_) ._.
        A_DT large_JJ number_NN of_IN sulfonated_JJ tetraphenylporphyrin_NN
        derivatives_NNS was_VBD also_RB evaluated_VBN ._. A_DT series_NN of_IN 15_CD metal_NN
        chelates_NNS of_IN tetraphenylporphyrin_NN tetrasulfonate_NN (_( TPPS_NNP 4_LS )_) was_VBD
        tested_VBN ,_, but_CC none_NN showed_VBD more_JJR than_IN 50_CD %_NN activity_NN at_IN 50_CD μg_NN /_NN mL_NN
        using_VBG either_CC the_DT WR_NNP or_CC IHD-J_NNP strains_NNS ;_: these_DT candidates_NNS
        therefore_RB were_VBD not_RB pursued_VBN ._. A_DT series_NN of_IN 12_CD
        tetraphenylporphyrin_NN derivatives_NNS made_VBN via_IN sulfonation_NN of_IN
        the_DT 2_CD -_: F_NN ,_, Cl_NNP and_CC Br_NNP ,_, the_DT 3_CD -_: F_NN and_CC Cl_NNP and_CC the_DT 4_CD -_: F_NN and_CC Cl_NNP
        tetraphenylporphyrins_NNS was_VBD evaluated_VBN ._. Many_JJ of_IN these_DT
        derivatives_NNS completely_RB blocked_VBN infection_NN by_IN both_DT strains_NNS at_IN
        concentrations_NNS of_IN 50_CD μg_NN /_NN mL_NN (_( Figure_NN 3_LS )_) ._. TPP_NNP 2_CD ClS_NNP and_CC TPP_NNP 2_CD FS_NNP
        were_VBD studied_VBN in_IN more_JJR detail_NN ._. These_DT two_CD derivatives_NNS had_VBD
        similar_JJ activities_NNS (_( within_IN a_DT factor_NN of_IN 4_LS )_) in_IN the_DT WR_NNP and_CC
        IHD-J_NNP assays_NNS ._. A_DT series_NN of_IN sulfonated_JJ derivatives_NNS of_IN the_DT
        2_CD ,_, 6_CD -_: difluoro_NN and_CC 2_CD ,_, 6_CD -_: dichlorotetraphenylporphyrins_NNS was_VBD also_RB
        studied_VBN ._. The_DT parent_NN compounds_NNS and_CC the_DT Co_NNP (_( III_NNP )_) chelate_NN of_IN
        the_DT difluoroporphyrin_NN completely_RB inhibited_VBD infection_NN at_IN 50_CD
        μg_NN /_NN mL_NN ;_: the_DT Co_NNP (_( III_NNP )_) chelate_NN had_VBD EC_NNP 
        50_CD values_NNS of_IN 1_CD ._. 6_CD (_( CV-_NNP 1_LS )_) and_CC 0_CD ._. 74_CD μg_NN /_NN mL_NN
        (_( BSC-_NNP 40_CD )_) in_IN the_DT WR_NNP assay_NN and_CC 0_CD ._. 44_CD μg_NN /_NN mL_NN (_( CV-_NNP 1_LS )_) in_IN the_DT IHD-J_NNP
        assay_NN ._. The_DT other_JJ compounds_NNS tested_VBN were_VBD less_RBR active_JJ ,_, i_NNP ._. e_SYM ._. ,_,
        at_IN 50_CD μg_NN /_NN mL_NN ,_, they_PRP inactivated_JJ the_DT virus_NN by_IN less_JJR than_IN 50_CD %_NN ._.
        Four_CD non-halogenated_JJ porphyrin_NN derivatives_NNS with_IN aryl_NN side_NN
        chains_NNS ,_, TNapS_NNP ,_, TAnthS_NNP ,_, TPP_NNP [_NN 2_CD ,_, 6_CD -_: (_( OH_NNP )_) 2_CD ]_NN and_CC TPP_NNP 4_CD OMeS_NNP ,_, had_VBD
        high_JJ activity_NN (_( Table_NNP 1_LS )_) ._. All_DT of_IN these_DT had_VBN EC_NNP 
        50_CD values_NNS of_IN <_NN 5_CD μg_NN /_NN mL_NN in_IN both_DT
        assays_NNS ._. TNapS_NNP and_CC TAnthS_NNP were_VBD more_RBR active_JJ against_IN the_DT IHD-J_NNP
        than_IN WR_NNP strain_NN (_( Table_NNP 1_LS )_) using_VBG CV-_NNP 1_CD cells_NNS ._. TPP_NNP [_NN 2_CD ,_, 6_CD -_: (_( OH_NNP )_) 2_CD ]_NN
        also_RB had_VBD high_JJ activity_NN ._. EC_NNP 
        50_CD values_NNS were_VBD 0_CD ._. 17_CD (_( CV-_NNP 1_LS )_) and_CC 0_CD ._. 19_CD
        (_( BSC-_NNP 40_CD )_) μg_NN /_NN mL_NN for_IN the_DT WR_NNP assay_NN ;_: and_CC 0_CD ._. 7_CD (_( CV-_NNP 1_LS )_) and_CC 0_CD ._. 32_CD
        μg_NN /_NN mL_NN (_( BSC-_NNP 40_CD )_) in_IN the_DT IHD-J_NNP assay_NN ._. TPP_NNP [_NN 2_CD ,_, 6_CD -_: (_( OH_NNP )_) 2_CD ]_NN is_VBZ a_DT
        neutral_JJ compound_NN with_IN eight_CD hydroxyl_NN groups_NNS (_( Figure_NN 1_LS )_) ;_:
        this_DT may_MD give_VB it_PRP amphiphilic_JJ properties_NNS that_WDT could_MD play_VB a_DT
        role_NN in_IN blocking_VBG infection_NN ._.
        Approximately_RB 25_CD sulfonated_JJ phthalocyanines_NNS (_( PcS_NNP )_) were_VBD
        evaluated_VBN ._. Only_RB the_DT copper_NN and_CC chromium_NN PcS_NNP were_VBD able_JJ to_TO
        inhibit_VB viral_JJ infection_NN ._. The_DT copper_NN phthalocyanine_NN
        sulfonate_NN only_RB had_VBD an_DT EC_NNP 
        50_CD of_IN approximately_RB 50_CD μg_NN /_NN mL_NN in_IN the_DT WR_NNP
        assay_NN in_IN both_DT cell_NN lines_NNS ._. It_PRP was_VBD somewhat_RB more_RBR active_JJ in_IN
        the_DT IHD-J_NNP assays_NNS ,_, but_CC the_DT sulfonated_JJ phthalocyanines_NNS were_VBD
        not_RB studied_VBN further_RB ._.
        Since_IN there_EX are_VBP major_JJ differences_NNS in_IN surface_NN antigens_NNS ,_,
        and_CC presumably_RB in_IN the_DT host_NN cell_NN receptors_NNS ,_, between_IN the_DT
        intracellular_NN and_CC extracellular_NN particles_NNS of_IN VV_NNP [_NN 10_CD 11_CD 12_CD
        ]_NN ,_, we_PRP also_RB compared_VBD the_DT sensitivity_NN of_IN the_DT two_CD forms_NNS to_TO
        the_DT compounds_NNS to_TO be_VB tested_VBN ._. Generally_RB ,_, the_DT compounds_NNS tested_VBN
        were_VBD highly_RB effective_JJ against_IN both_DT forms_NNS (_( Table_NNP 1_LS )_) ._.
        Comparison_NNP of_IN the_DT intracellular_NN mature_VBP virion_NN (_( IMV_NNP ,_, third_JJ
        column_NN in_IN Table_NNP 1_LS )_) and_CC extracellular_NN enveloped_JJ virion_NN (_( EEV_NNP )_)
        forms_NNS of_IN the_DT IHD-J_NNP strain_NN showed_VBD differences_NNS in_IN activity_NN of_IN
        some_DT compounds_NNS in_IN blocking_VBG infection_NN by_IN the_DT two_CD forms_NNS of_IN
        the_DT virus_NN ._. These_DT results_NNS suggest_VBP that_IN the_DT tetrapyrroles_NNS may_MD
        be_VB binding_JJ to_TO different_JJ components_NNS on_IN the_DT surface_NN of_IN the_DT
        two_CD forms_NNS of_IN the_DT virus_NN and_CC thus_RB show_VB differences_NNS in_IN
        efficiency_NN of_IN preventing_VBG virus_NN infection_NN ._.
        The_DT active_JJ compounds_NNS exhibited_VBN very_RB low_JJ to_TO moderate_VB
        toxicity_NN in_IN assays_NNS for_IN their_PRP$ effects_NNS on_IN cell_NN viability_NN
        (_( Table_NNP 2_LS )_) ._. Therapeutic_NNP ratios_NNS ,_, calculated_VBN as_IN CC_NNP 
        50_CD /_NN EC_NNP 
        50_CD ,_, were_VBD found_VBN to_TO be_VB in_IN a_DT range_NN from_IN 64_CD
        -_: 1400_CD ,_, with_IN the_DT exception_NN of_IN ZnPPIX_NNP ,_, for_IN which_WDT the_DT ratios_NNS
        were_VBD in_IN the_DT range_NN of_IN 1_CD -_: 3_CD ._. The_DT compounds_NNS were_VBD also_RB tested_VBN
        in_IN CV-_NNP 1_CD cells_NNS and_CC a_DT human_JJ cell_NN line_NN (_( HeLaS_NNP 3_LS )_) for_IN their_PRP$
        effect_NN on_IN cell_NN growth_NN (_( Table_NNP 3_LS )_) ._. The_DT compounds_NNS tested_VBN
        generally_RB inhibited_VBD CV-_NNP 1_CD cell_NN growth_NN at_IN high_JJ
        concentrations_NNS ,_, and_CC 3_CD H-_NNP thymidine_NN uptake_NN in_IN HeLa_NNP cells_NNS by_IN
        50_CD %_NN only_RB at_IN concentrations_NNS above_IN 20_CD μg_NN /_NN mL_NN except_IN for_IN
        Co_NNP (_( III_NNP )_) TPP_NNP (_( 2_CD ,_, 6_CD -_: F_NN 2_LS )_) S_NNP (_( CC_NNP 
        50_CD <_NN 5_CD μg_NN /_NN mL_NN )_) ._.
        The_DT ability_NN of_IN a_DT number_NN of_IN tetrapyrroles_NNS to_TO inhibit_VB
        virus_NN replication_NN was_VBD determined_VBN in_IN CV-_NNP 1_CD cells_NNS infected_VBN
        with_IN the_DT WR_NNP strain_NN in_IN the_DT absence_NN of_IN compounds_NNS ._. Following_VBG
        virus_NN adsorption_NN (_( 2_CD h_NN )_) ,_, compounds_NNS in_IN growth_NN medium_NN were_VBD
        added_VBN to_TO the_DT cells_NNS ._. After_IN 16_CD h_NN post-infection_JJ ,_, cells_NNS and_CC
        media_NNS were_VBD collected_VBN ,_, virus_NN was_VBD released_VBN by_IN freezing_NN and_CC
        thawing_VBG and_CC virus_NN yields_NNS determined_VBN by_IN plaque_NN assay_NN ._.
        Reduction_NNP of_IN virus_NN yield_NN was_VBD observed_VBN with_IN all_DT compounds_NNS
        assayed_JJ (_( Table_NNP 4_LS )_) ,_, with_IN most_JJS compounds_NNS resulting_VBG in_IN 95_CD -_:
        99_CD %_NN reduction_NN at_IN 50_CD μg_NN /_NN mL_NN ._. These_DT results_NNS indicate_VBP that_IN
        infectious_JJ virus_NN production_NN is_VBZ being_VBG inhibited_VBD by_IN these_DT
        compounds_NNS ._.
        These_DT results_NNS were_VBD compared_VBN to_TO those_DT of_IN other_JJ
        experiments_NNS in_IN which_WDT the_DT compounds_NNS were_VBD removed_VBN before_IN
        viral_JJ titration_NN was_VBD done_VBN (_( Table_NNP 5_LS )_) ._. The_DT effect_NN on_IN viral_JJ
        yield_NN was_VBD found_VBN to_TO be_VB significantly_RB reduced_VBN when_WRB the_DT
        compounds_NNS were_VBD removed_VBN prior_RB to_TO harvest_NN ,_, indicating_VBG that_IN
        the_DT inhibitory_NN effect_NN occurs_VBZ predominantly_RB after_IN viral_JJ
        release_NN ._. Using_VBG a_DT lower_JJR moi_FW (_( 0_CD ._. 001_CD pfu_NN /_NN cell_NN )_) ,_, and_CC removing_VBG
        the_DT compounds_NNS before_IN the_DT viral_JJ harvest_NN resulted_VBD in_IN
        reduction_NN of_IN viral_JJ yields_NNS by_IN as_RB much_JJ as_IN 98_CD %_NN (_( Table_NNP 6_CD )_) ,_,
        indicating_VBG that_IN the_DT compounds_NNS block_VBP multiple_JJ cycle_NN
        replication_NN of_IN the_DT virus_NN ._. Inhibition_NNP of_IN virus_NN spread_VBD by_IN
        these_DT compounds_NNS has_VBZ also_RB been_VBN observed_VBN when_WRB the_DT
        tetrapyrroles_NNS were_VBD included_VBN in_IN the_DT overlay_NN medium_NN in_IN a_DT
        plaque_NN assay_NN ._. After_IN 44_CD h_NN ,_, the_DT cell_NN monolayers_NNS were_VBD stained_JJ
        and_CC the_DT plaque_NN numbers_NNS determined_VBN ._. We_PRP observed_VBD substantial_JJ
        reductions_NNS in_IN plaque_NN numbers_NNS and_CC size_NN (_( data_NNS not_RB shown_VBN )_)
        indicating_VBG inhibition_NN of_IN both_DT virus_NN infection_NN and_CC
        spread_NN ._.
      
      
        Discussion_NNP
        Photoinactivation_NNP of_IN viruses_NNS by_IN diamagnetic_JJ porphyrins_NNS
        and_CC phthalocyanines_NNS has_VBZ been_VBN widely_RB studied_VBN [_NN 13_CD 14_CD 15_CD 16_CD
        17_CD 18_CD 19_CD 20_CD ]_NN ._. Photoactivation_NNP involves_VBZ absorption_NN of_IN
        light_JJ by_IN the_DT tetrapyrrole_NN with_IN resulting_VBG production_NN of_IN free_JJ
        radicals_NNS and_CC singlet_NN oxygen_NN ._. In_IN the_DT current_JJ study_NN ,_,
        inhibition_NN of_IN vaccinia_NN infection_NN is_VBZ not_RB due_JJ to_TO
        photoactivation_NN of_IN the_DT tetrapyrroles_NNS ,_, as_IN shown_VBN by_IN two_CD
        aspects_NNS of_IN the_DT experiments_NNS ._. First_LS ,_, there_EX was_VBD little_JJ
        exposure_NN to_TO light_VB during_IN experiments_NNS ,_, with_IN no_DT additional_JJ
        irradiation_NN ._. Second_JJ ,_, we_PRP observed_VBD that_IN the_DT extent_NN of_IN
        inactivation_NN was_VBD not_RB a_DT function_NN of_IN the_DT spin_NN state_NN
        (_( diamagnetic_JJ or_CC paramagnetic_JJ )_) for_IN metal_NN chelates_NNS of_IN the_DT
        porphyrins_NNS and_CC phthalocyanines_NNS ._. Only_RB diamagnetic_JJ
        tetrapyrroles_NNS are_VBP able_JJ to_TO inhibit_VB viruses_NNS via_IN
        photoinactivation_NN ;_: the_DT excited_VBN states_NNS of_IN the_DT paramagnetic_JJ
        derivatives_NNS have_VBP short_JJ half-lives_JJ and_CC do_VBP not_RB give_VB
        significant_JJ amounts_NNS of_IN free_JJ radicals_NNS or_CC singlet_NN oxygen_NN ._.
        Tetrapyrroles_NNP previously_RB have_VBP been_VBN reported_VBN to_TO inhibit_VB
        certain_JJ other_JJ viruses_NNS by_IN mechanisms_NNS not_RB involving_VBG
        photoactivation_NN ._. A_DT cationic_JJ phthalocyanine_NN was_VBD reported_VBN to_TO
        inhibit_VB human_JJ rhinovirus_JJ type_NN 5_CD (_( RV-_NNP 5_LS )_) infection_NN [_NN 21_CD ]_NN ._.
        Selected_JJ porphyrin_NN derivatives_NNS inhibit_VBP specific_JJ viral_JJ
        targets_NNS including_VBG retroviral_NN reverse_NN transcriptase_NN [_NN 22_CD 23_CD
        24_CD 25_CD 26_CD ]_NN and_CC HIV-_NNP 1_CD protease_NN [_NN 27_CD ]_NN ._.
        In_IN previous_JJ studies_NNS of_IN the_DT antiviral_JJ effects_NNS of_IN
        porphyrins_NNS ,_, Song_NN et_CC al_NN ._. investigated_VBD the_DT antiviral_JJ effects_NNS
        of_IN Fe_NNP 
        
        meso_NN -_: tetrakis_NNS (_( 3_CD ,_, 4_CD -_: disulfonatomesityl_NN )_) porphyrin_NN
        (_( FeTMPS_NNP )_) ,_, and_CC 
        meso_NN -_: tetra_NN (_( 4_CD -_: carboxyphenyl_NN )_) porphyrin_NN
        (_( TPPC_NNP )_) and_CC its_PRP$ iron_NN and_CC nickel_NN chelates_NNS for_IN a_DT variety_NN of_IN
        viruses_NNS [_NN 28_CD ]_NN ._. EC_NNP 
        50_CD s_VBZ were_VBD generally_RB 20_CD μg_NN /_NN mL_NN or_CC greater_JJR
        for_IN VV_NNP ,_, VSV_NNP ,_, HSV-_NNP 1_CD ,_, HSV-_NNP 2_CD ,_, Coxsackie_NNP virus_NN B_NNP 4_CD and_CC
        poliovirus-_NN 1_CD ._. FeTMPS_NNP showed_VBD activity_NN in_IN this_DT range_NN also_RB for_IN
        parainfluenza-_NN 3_CD ,_, reovirus-_NN 1_CD ,_, and_CC Semliki_NNP forest_NN virus_NN ._.
        FeTMPS_NNP was_VBD more_RBR active_JJ for_IN sindbis_NNS virus_NN ,_, VZV_NNP and_CC CMV_NNP ,_, with_IN
        EC_NNP 
        50_CD s_VBZ of_IN 5_CD to_TO 25_CD μg_NN /_NN mL_NN ._. Fe_NNP and_CC Ni_NNP TPPC_NNP
        were_VBD also_RB quite_RB active_JJ against_IN CMV_NNP ._.
        Porphyrins_NNP and_CC metalloporphyrins_NNS have_VBP also_RB been_VBN shown_VBN to_TO
        have_VB antiviral_JJ activity_NN against_IN HIV_NNP [_NN 23_CD 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD
        30_CD 31_CD 32_CD 33_CD 34_CD 35_CD 36_CD 37_CD 38_CD ]_NN ._. Previous_JJ studies_NNS indicated_VBD
        that_IN some_DT porphyrins_NNS inhibit_VBP the_DT interaction_NN between_IN the_DT
        virus_NN envelope_NN protein_NN and_CC its_PRP$ receptors_NNS [_NN 28_CD 31_CD 32_CD 33_CD 34_CD
        35_CD 36_CD 37_CD 38_CD ]_NN ._. We_PRP have_VBP shown_VBN also_RB that_IN porphyrins_NNS block_VBP
        infection_NN by_IN HIV-_NNP 1_CD and_CC that_IN this_DT activity_NN appears_VBZ to_TO be_VB a_DT
        result_NN of_IN an_DT interaction_NN with_IN the_DT envelope_NN protein_NN [_NN 38_CD ]_NN ._.
        In_IN this_DT regard_NN ,_, the_DT compounds_NNS that_WDT were_VBD active_JJ in_IN blocking_VBG
        infection_NN by_IN HIV-_NNP 1_CD tended_VBD to_TO be_VB sulfonated_JJ compounds_NNS or_CC
        other_JJ negatively_RB charged_VBN compounds_NNS ._. In_IN the_DT present_JJ study_NN ,_,
        it_PRP is_VBZ of_IN interest_NN that_IN the_DT uncharged_JJ molecule_NN
        TPP_NNP [_NN 2_CD ,_, 6_CD -_: (_( OH_NNP )_) 2_CD ]_NN was_VBD one_CD of_IN the_DT most_RBS active_JJ compounds_NNS tested_VBN ._.
        This_DT result_NN indicates_VBZ that_IN the_DT activity_NN of_IN this_DT compound_NN
        with_IN VV_NNP is_VBZ not_RB merely_RB a_DT reflection_NN of_IN an_DT interaction_NN
        between_IN a_DT negatively_RB charged_VBN molecule_NN and_CC positively_RB
        charged_VBN sites_NNS on_IN the_DT viral_JJ surface_NN ,_, but_CC that_IN other_JJ
        structural_JJ features_NNS are_VBP important_JJ for_IN interaction_NN with_IN
        viral_JJ proteins_NNS ._.
        Although_IN the_DT WR_NNP and_CC IHD-J_NNP strains_NNS exhibited_VBN similar_JJ
        sensitivity_NN to_TO most_JJS of_IN the_DT compounds_NNS tested_VBN ,_, some_DT
        differences_NNS in_IN their_PRP$ relative_JJ sensitivity_NN was_VBD observed_VBN ._. The_DT
        WR_NNP strain_NN was_VBD 3_CD -_: to_TO 6_CD -_: fold_VB less_RBR sensitive_JJ than_IN IHD-J_NNP to_TO
        several_JJ compounds_NNS including_VBG TAnthPS_NNP ,_, CuHPIX_NNP ,_, and_CC TPP_NNP 2_CD FS_NNP ,_,
        but_CC was_VBD about_IN 3_CD -_: fold_VB more_RBR sensitive_JJ to_TO inhibition_NN by_IN
        TPP_NNP [_NN 2_CD ,_, 6_CD (_( OH_NNP )_) 2_CD ]_NN ._. These_DT results_NNS support_VBP the_DT conclusion_NN that_IN
        the_DT compounds_NNS block_VBP infection_NN by_IN interacting_VBG with_IN specific_JJ
        viral_JJ protein_NN (_( s_VBZ )_) ,_, and_CC that_IN strain-specific_JJ differences_NNS in_IN
        protein_NN structures_NNS determine_VBP the_DT differences_NNS in_IN
        sensitivities_NNS to_TO specific_JJ compounds_NNS ._. The_DT sensitivity_NN of_IN the_DT
        activity_NN to_TO relatively_RB small_JJ structural_JJ changes_NNS in_IN our_PRP$ work_NN
        indicates_VBZ either_CC that_DT amphiphilicity_NN and_CC steric_JJ and_CC
        specific_JJ axial_NN ligand_NN effects_NNS significantly_RB control_VBP binding_VBG
        to_TO the_DT virion_NN target_NN ,_, or_CC that_IN more_JJR than_IN one_CD mechanism_NN of_IN
        inhibition_NN is_VBZ operational_JJ ._.
        EC_NNP 
        50_CD data_NNS obtained_VBN from_IN both_DT viruses_NNS
        studied_VBN ranged_VBD from_IN 0_CD ._. 05_CD to_TO 40_CD μM_NN ._. This_DT range_NN is_VBZ comparable_JJ
        to_TO that_DT observed_VBD for_IN other_JJ compounds_NNS active_JJ against_IN
        vaccinia_NN ._. For_IN example_NN ,_, cidofovir_NN ,_, an_DT acyclic_JJ nucleoside_NN
        with_IN activity_NN against_IN a_DT variety_NN of_IN DNA_NNP viruses_NNS ,_, used_VBD
        clinically_RB in_IN some_DT instances_NNS [_NN 39_CD ]_NN ,_, has_VBZ been_VBN shown_VBN to_TO be_VB
        effective_JJ against_IN a_DT number_NN of_IN poxviruses_NNS with_IN the_DT following_VBG
        EC_NNP 
        50_CD values_NNS :_: 2_CD ._. 3_CD μM_NN (_( camelpox_NN )_) ,_, 46_CD ._. 2_LS μM_NN
        (_( vaccinia_NN )_) ,_, 27_CD μM_NN (_( monkeypox_NN )_) and_CC 58_CD μM_NN (_( cowpox_NN )_) [_NN 40_CD 41_CD ]_NN
        ._. Other_JJ classes_NNS of_IN compounds_NNS have_VBP been_VBN tested_VBN for_IN their_PRP$
        effectiveness_NN against_IN vaccinia_NN virus_NN including_VBG the_DT IMP_NNP
        dehydrogenase_NN inhibitors_NNS (_( EC_NNP 
        50_CD 4_CD -_: 100_CD μg_NN /_NN mL_NN )_) ,_, OMP_NNP decarboxylase_NN
        inhibitors_NNS (_( 0_CD ._. 02_CD -_: 15_CD μg_NN /_NN mL_NN )_) ,_, and_CC polyanionic_JJ compounds_NNS
        (_( 0_CD ._. 1_LS -_: 20_CD μg_NN /_NN mL_NN )_) [_NN 6_CD ]_NN ._.
        In_IN conclusion_NN ,_, we_PRP observed_VBD that_IN both_DT porphyrins_NNS and_CC
        phthalocyanines_NNS have_VBP substantial_JJ antiviral_JJ activity_NN against_IN
        vaccinia_NN virus_NN ._. Examples_NNS of_IN the_DT natural_JJ porphyrin_NN ,_,
        sulfonated_JJ tetraphenylporphyrin_NN ,_, neutral_JJ
        tetraphenylporphyrin_NN and_CC sulfonated_JJ phthalocyanine_NN classes_NNS
        were_VBD all_DT found_VBD to_TO be_VB active_JJ ._. These_DT results_NNS ,_, as_RB well_RB as_IN the_DT
        high_JJ therapeutic_JJ ratios_NNS observed_VBD ,_, indicate_VBP that_IN these_DT
        compounds_NNS represent_VBP attractive_JJ candidates_NNS as_IN antiviral_JJ
        agents_NNS to_TO control_VB poxvirus_JJ infection_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Author_NN Contributions_NNP
        Author_NN ARMC_NNP carried_VBD out_IN most_JJS of_IN the_DT experiments_NNS and_CC
        wrote_VBD sections_NNS of_IN the_DT manuscript_NN ._. Author_NN DWD_NNP supplied_VBD
        compounds_NNS for_IN the_DT study_NN ,_, performed_VBD the_DT data_NNS analysis_NN and_CC
        wrote_VBD sections_NNS of_IN the_DT manuscript_NN ._. Author_NN ANV_NNP designed_VBD
        experiments_NNS and_CC performed_VBN initial_JJ experiments_NNS ._. Author_NN LGM_NNP
        supplied_VBD compounds_NNS for_IN the_DT study_NN ._. Author_NN RWC_NNP designed_VBD
        experiments_NNS and_CC wrote_VBD sections_NNS of_IN the_DT manuscript_NN ._.
      
    
  
